📰 Peter Bak News
Page 2 - Peter Bak News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Peter Bak. Real-time updates on events, politics, business and more.
April 4, 2022
Gratomic Inc has kicked off its 1 million Namibian dollar (around C$86,000) improvement program at the J.S. Herero Primary School by handing over of 100...
February 3, 2022
Light can be used to stimulate light-sensitive receptors in order to turn brain cells “on” and “off” at the flip of a switch,...
June 4, 2021
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2021) - Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company"), a leader in Revenue Cycle Management ("RCM") and healthcare technology
June 3, 2021
Kovo HealthTech Corporation to Begin Trading on TSX Venture Exchange Vancouver, British Columbia--(Newsfile Corp. - June 3, 2021) - Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company"), a leader in Revenue Cycle Management ("RCM") and healthcare technology, is pleased to announce that its common shares will commence trading on the TSX Venture Exchange (the "TSXV") at the open of the market on June 4, 2021 under the symbol "KOVO". Kovo is a growing healthcare technology and servic...
December 21, 2020
12.20.20 -- Cleaning Process Development: Time To Clean Studies & The Cleaning Assurance Level For Pharmaceutical Products By Ruijin Song and Andrew Walsh, Center for Pharmaceutical Cleaning Innovation (CPCI) A simple time-to-clean study can provide a rapid and efficient way to evaluate the behavior of a product during cleaning and obtain a reasonable estimate of the actual amount of time needed to achieve acceptable cleaning. By Mavra Nasir, Ph.D., Crystal ...
December 14, 2020
Analysis Of The Non-alcoholic Steatohepatitis (NASH) Drug Pipeline & Market: The M&A And Commercial Landscape By Mavra Nasir, Ph.D., Crystal Hsu, and Peter Bak, Ph.D., Back Bay Life Science Advisors In Part 1 and Part 2 of this three-part series, we covered the varied complexities of NASH driving an extremely challenging development landscape, along with the growing prevalence of NASH that has the life sciences industry in a race to develop a successful asset. In this last part of the series, ...